<DOC>
	<DOCNO>NCT00049660</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know capecitabine effective vinorelbine treat metastatic breast cancer . PURPOSE : Randomized phase II/III trial compare effectiveness capecitabine vinorelbine treat woman metastatic breast cancer previously treat chemotherapy .</brief_summary>
	<brief_title>Capecitabine Compared With Vinorelbine Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Phase II Study : - Compare response rate woman previously treat metastatic breast cancer treat capecitabine v vinorelbine . - Compare duration response patient treat drug . Phase III Study : - Compare overall progression-free survival patient treat drug . - Compare time treatment failure patient treat drug . - Compare overall safety drug patient . - Compare quality life clinical benefit response patient treat drug . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center taxane resistance ( refractory v resistant v sensitive ) . - Phase II : Patients randomize 1 2 treatment arm . - Arm I : Patients receive vinorelbine IV day 1 8 . Courses repeat every 21 day . - Arm II : Patients receive oral capecitabine twice daily day 1-14 . Courses repeat every 21 day . In arm , treatment continue absence progression unacceptable toxicity . If sufficient response rate determine phase II , phase III study initiate . - Phase III : Patients randomize receive treatment phase II . Quality life assess prior randomization , week 3 , 6 , 9 , 18 , 24 , 30 , every 12 week disease progression . Clinical benefit response assess daily patient study . Patients follow every 6 week disease progression every 12 week thereafter . PROJECTED ACCRUAL : A total 72 patient ( 36 per treatment arm ) accrue phase II study total 406-452 patient ( 203-226 per treatment arm ) accrue phase III study within 18.5 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Metastatic disease Prior treatment taxanes metastatic , adjuvant , neoadjuvant set Taxaneresistant disease allow regardless duration prior therapy NOTE : Resistant disease define progression within 12 week taxane therapy metastatic disease diseasefree interval le 12 month neoadjuvant adjuvant therapy taxane Taxanesensitive disease allow least 4 prior course receive NOTE : Sensitive disease define progression occur 12 week taxane therapy metastatic disease 12 month neoadjuvant adjuvant therapy taxane Prior treatment anthracyclines metastatic disease adjuvant treatment OR medical contraindication treatment anthracyclines At least one unidimensionally measurable lesion ( phase II study ) No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.25 time upper limit normal ( ULN ) Transaminases great 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal Creatinine clearance great 50 mL/min Cardiovascular No symptomatic ventricular arrhythmia No clinically significant congestive heart failure No clinical ECG evidence myocardial infarction within past 12 month No significant coronary artery disease Other Not pregnant nursing Fertile patient must use effective contraception No prior malignancy within past 5 year except contralateral breast cancer , nonmelanoma skin cancer , adequately treat carcinoma situ cervix No know prior sensitivity fluoropyrimidines , include fluorouracil No preexisting grade 2 great neurotoxicity No know malabsorption upper gastrointestinal abnormality would affect absorption study drug No psychological , familial , sociological , geographical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic therapy Chemotherapy See Disease Characteristics No 2 prior chemotherapy line metastatic disease No prior capecitabine , vinca alkaloid , continuous fluorouracil No concurrent chemotherapy Endocrine therapy Prior hormonal therapy allow No concurrent hormonal therapy Radiotherapy No concurrent radiotherapy Surgery Not specify Other Bisphosphonate therapy treatment prevention bony metastasis allow initiated prior study No concurrent investigational treatment No concurrent brivudine capecitabine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
</DOC>